The effect of N-(3-phenyl-2-propenyl)-1-deoxynojirimycin (ppDNM) on the lectin binding to HIV-1 glycoprotein was analyzed by using biotinylated lectins of various sugar specificities as probes. ppDNM potentially inhibited HIV-1-induced syncytium formation and viral infectivity of HIV-1 without cytotoxicity. The lectin binding assay showed that ppDNM treatment reduced Con A binding to gp120 of HIV-1.
1-Deoxynojirimycin, a potent glucose analog, inhibits α-glucosidase I and II effectively. Its derivative, N-5-Carboxypentyl-1-deoxynojirimycin, serves as a ligand for glucosidase I and II purification, utilizing carboxypentyl groups for affinity chromatography resin linkage. Furthermore, N-5-Carboxypentyl-1-deoxynojirimycin demonstrates comparable or superior inhibition of glucosidase compared to 1-deoxynojirimycin, with inhibition constants (Ki) of 0.45 µM and 2.1 µM, respectively, for pig liver glucosidase I.
Deoxynojirimycin (dNM) tetrabenzyl ether is an intermediate for the synthesis of glucosylceramide synthase inhibitors such as 1-dNM, a glucose analog that potently inhibits α-glucosidase I and II.